Traws Pharma approves 1-for-25 reverse stock split, regains Nasdaq equity compliance

Traws Pharma, Inc.

Board approved 1-for-25 reverse split; effective Sept 20, trading split-adjusted Sept 23.
Authorized shares increased from 125M to 250M; stockholders approved conversion of Series C Preferred.
Director James Marino resigned; Luba Greenwood appointed to board and committees.
Company believes it now satisfies Nasdaq $2.5M stockholders' equity requirement after conversion; delisting risk remains.
Annual meeting set for Oct 31, 2024; shareholder proposals due Sept 26, 2024.

item 5.02 item 5.03 item 5.07 item 5.08 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

James J. Marino

Director

TRAW · Traws Pharma, Inc.

Effective: 2024-09-16
Successor: Luba Greenwood
Filed: September 17, 2024, 7:59 PM ET

On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.

Appointed

Luba Greenwood

Director

TRAW · Traws Pharma, Inc.

Effective: 2024-09-16
Filed: September 17, 2024, 7:59 PM ET

the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

James J. Marino resigned as Director at Traws Pharma, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 16, 2024, James J. Marino, a member of the Board of Directors (the “Board”) of Traws Pharma, Inc. (the “Company”), resigned as a director.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Luba Greenwood was appointed as Director at Traws Pharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

the Board appointed Luba Greenwood to the Board to fill the vacancy created by Mr. Marino’s resignation with a term expiring at the Company’s 2024 annual meeting of stockholders.

View on SEC.gov

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-100709

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.